(Q33394235)

English

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ute Eisenberger

object named as

Ute Eisenberger

6

0 references

5

object named as

Petra Reinke

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Klemens Budde

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas Becker

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Wolfgang Arns

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Claudia Sommerer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stefan Kramer

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Wolfgang Fischer

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Harald Gschaidmeier

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frank Pietruck

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ZEUS Study Investigators

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

19 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

377

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9768

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

837-847

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Reduced exposure to calcineurin inhibitors in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcineurin inhibitor-free immunosuppression in kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcineurin inhibitor nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Protocol conversion from a calcineurin inhibitor based therapy to sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit-risk assessment of sirolimus in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate markers for long-term renal allograft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962318-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)62318-5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394235&oldid=1536428058"